Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Capital Expenditures (2024 - 2025)

Zenas BioPharma (ZBIO) has 2 years of Capital Expenditures data on record, last reported at $18000.0 in Q1 2025.

  • For Q1 2025, Capital Expenditures fell 18.18% year-over-year to $18000.0; the TTM value through Sep 2025 reached $92000.0, changed N/A, while the annual FY2024 figure was $131000.0, 670.59% up from the prior year.
  • Capital Expenditures reached $18000.0 in Q1 2025 per ZBIO's latest filing, down from $74000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $74000.0 in Q4 2024 and bottomed at $18000.0 in Q1 2025.